登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、担保情况概述 苏宁环球股份有限公司（以下简称"公司"）第十一届董事会第七次会议、第十一届监事会第七次会议、 2024年年度股东大会，审议通过了《关于2025年对子公司预计担保额度的议案》，公司、全资子公司及 控股子公司（包括但不限于净资产负债率超过70%的子公司），拟在2025年度向金融机构融资，公司及 子公司（含控股子公司）拟为其银行及其它金融机构信贷业务以及其它业务提供担保，在授权有效期内 提供的担保总额不超过人民币38.2亿元。实际担保金额、种类、期限等以合同为准，授权经营管理层具 体办理相关事宜，有效期自本事项经公司2024年年度股东大会审议批准之日起至2025年年度股东大会审 议之日止。 具体内容详见公司于巨潮资讯网http://www.cninfo.com.cn披露的《关于2025年对子公司预计担保额度的 公告》（公告编号：2025-009）等相关公告。 二、担保进展情况 近日，公司、公司全资子公司南京浦东房地产开发有限公司（以下简称"浦东地产"） ...

苏宁环球股份有限公司 关于为子公司申请银行授信提供担保的 进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、担保情况概述 苏宁环球股份有限公司（以下简称"公司"）第十一届董事会第 七次会议、第十一届监事会第七次会议、2024 年年度股东大会，审 议通过了《关于 2025 年对子公司预计担保额度的议案》，公司、全 资子公司及控股子公司（包括但不限于净资产负债率超过 70%的子公 司），拟在 2025 年度向金融机构融资，公司及子公司（含控股子公 司）拟为其银行及其它金融机构信贷业务以及其它业务提供担保，在 授权有效期内提供的担保总额不超过人民币 38.2 亿元。实际担保金 额、种类、期限等以合同为准，授权经营管理层具体办理相关事宜， 有效期自本事项经公司 2024 年年度股东大会审议批准之日起至 2025 年年度股东大会审议之日止。 具体内容详见公司于巨潮资讯网 http://www.cninfo.com.cn 披露 的《关于 2025 年对子公司预计担保额度的公告》 （公告编号：2025-009） 证券代码：000718 证券简称：苏宁环球 公告编 ...

Group 1 - The core point of the announcement is that Suning Universal has approved a guarantee limit of 3.82 billion yuan for its subsidiaries, with an actual guarantee balance of 1.191 billion yuan, which accounts for 12.65% of the company's latest audited net assets attributable to shareholders [2] - The company and its controlling subsidiaries do not have any overdue guarantees [2]

证券代码：000718 证券简称：苏宁环球 公告编号：2025-021 苏宁环球股份有限公司 关于为子公司申请银行授信提供担保的 进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、担保情况概述 苏宁环球股份有限公司（以下简称"公司"）第十一届董事会第 七次会议、第十一届监事会第七次会议、2024 年年度股东大会，审 议通过了《关于 2025 年对子公司预计担保额度的议案》，公司、全 资子公司及控股子公司（包括但不限于净资产负债率超过 70%的子公 司），拟在 2025 年度向金融机构融资，公司及子公司（含控股子公 司）拟为其银行及其它金融机构信贷业务以及其它业务提供担保，在 授权有效期内提供的担保总额不超过人民币 38.2 亿元。实际担保金 额、种类、期限等以合同为准，授权经营管理层具体办理相关事宜， 有效期自本事项经公司 2024 年年度股东大会审议批准之日起至 2025 年年度股东大会审议之日止。 具体内容详见公司于巨潮资讯网 http://www.cninfo.com.cn 披露 的《关于2025 年对子公司预计担保额度的公告》（公告编号：2 ...

Group 1 - The core point of the announcement is the approval of the 2024 annual profit distribution plan by the company's shareholders, which includes a cash dividend distribution of 0.40 RMB per 10 shares [1][3]. - The total number of shares for the distribution is 3,034,636,384, resulting in a total cash dividend payout of 121,385,455.36 RMB (including tax) [1][2]. - The dividend distribution will not include stock bonuses or capital reserve transfers to increase share capital, and the company plans to maintain the per-share distribution ratio even if the total number of shares changes due to actions like issuance or repurchase before the dividend record date [1][2]. Group 2 - The record date for the dividend distribution is set for July 24, 2025, and the ex-dividend date is July 25, 2025 [2]. - The distribution will be made directly to the accounts of all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the record date [2]. - The company will not withhold individual income tax for certain investors, and tax rates will vary based on the holding period of the shares [1][2].

证券代码：000718 证券简称：苏宁环球 公告编号：2025-020 苏宁环球股份有限公司 二、权益分派方案 本公司 2024 年年度权益分派方案为:以公司现有总股本 3,034,636,384 股为基数，向全体股东每 10 股派 0.400000 元人民币现 金（含税；扣税后，通过深股通持有股份的香港市场投资者、境外机 构（含 QFII、RQFII）以及持有首发前限售股的个人和证券投资基金每 10 股派 0.360000 元；持有首发后限售股、股权激励限售股及无限售 流通股的个人股息红利税实行差别化税率征收，本公司暂不扣缴个人 所得税，待个人转让股票时，根据其持股期限计算应纳税额【注】； 持有首发后限售股、股权激励限售股及无限售流通股的证券投资基金 所涉红利税，对香港投资者持有基金份额部分按 10%征收，对内地投 资者持有基金份额部分实行差别化税率征收）。 【注：根据先进先出的原则，以投资者证券账户为单位计算持股 期限，持股 1 个月（含 1 个月）以内，每 10 股补缴税款 0.080000 元； 持股 1 个月以上至 1 年（含 1 年）的，每 10 股补缴税款 0.040000 元； 持股超过 1 ...

证券代码：000718 证券简称：苏宁环球 公告编号：2025-019 苏宁环球股份有限公司 关于为子公司申请银行授信提供担保的 进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、担保情况概述 苏宁环球股份有限公司（以下简称"公司"）第十一届董事会第 七次会议、第十一届监事会第七次会议、2024 年年度股东大会，审 议通过了《关于 2025 年对子公司预计担保额度的议案》，公司、全 资子公司及控股子公司（包括但不限于净资产负债率超过 70%的子公 司），拟在 2025 年度向金融机构融资，公司及子公司（含控股子公 司）拟为其银行及其它金融机构信贷业务以及其它业务提供担保，在 授权有效期内提供的担保总额不超过人民币 38.2 亿元。实际担保金 额、种类、期限等以合同为准，授权经营管理层具体办理相关事宜， 有效期自本事项经公司 2024 年年度股东大会审议批准之日起至 2025 年年度股东大会审议之日止。 具体内容详见公司于巨潮资讯网 http://www.cninfo.com.cn 披露 的《关于2025 年对子公司预计担保额度的公告》（公告编号：2 ...

Group 1: Company Overview and Strategy - The company focuses on real estate development and sales, with a strong presence in the Yangtze River Delta region, adhering to a "long-termism" philosophy and a strategy of "steady operation and progress" [2][3] - The company maintains a "low debt, high return" operational strategy while advancing its dual business model in real estate and medical aesthetics [2][3] Group 2: Real Estate Business Performance - The real estate sector remains under pressure, but market sales data is stabilizing; the company benefits from ample quality land reserves and low land costs, with a total land reserve of over 1.7 million square meters [3] - Key projects like Binjiang Yayuan and Rongjin Ruifu are performing well, with strong sales and high profitability [3][4] Group 3: Future Development Plans in Real Estate - The company plans to continue its high-profit and positive cash flow real estate projects, with new projects set to launch in advantageous areas in the second half of the year [4] - The company will focus on upgrading and launching premium projects while maintaining a stable pricing system [4] Group 4: Medical Aesthetics Business Performance - The company has established six medical aesthetics institutions, creating a distribution pattern across six cities, and is committed to compliance and quality management [5][6] - The revenue and profit from the medical aesthetics sector are gradually increasing, with expectations for significant growth in revenue share by 2026 as new institutions open in the Yangtze River Delta [6] Group 5: Market Conditions and Future Outlook for Medical Aesthetics - The medical aesthetics market is experiencing a slowdown, with increased concentration and the exit of smaller players; however, the company focuses on high-end clientele and maintains a stable pricing strategy [7][8] - The company aims to expand its medical aesthetics business while exploring new industries and opportunities for sustainable growth [8]

Group 1: Medical Aesthetics Business Development - The company plans to increase investment in the medical aesthetics sector, aiming to enhance the market recognition and reputation of the Suya Medical Aesthetics brand. In 2025, new medical aesthetics institutions are planned to open in Jiangsu and Shanghai [2][3] - In 2024, the medical aesthetics segment achieved revenue of 179 million yuan and is currently profitable. The company will continue to focus on self-built facilities and expand in high-consumption areas like the Yangtze River Delta [5][6] Group 2: Shareholder Engagement and Stock Performance - In 2024, the actual controller and some executives completed a round of share buybacks, demonstrating confidence in the company's long-term investment value [3][4] - The company is committed to a "long-termism" approach, focusing on stable operations and long-term value creation, despite current market pressures affecting stock prices [4][6] Group 3: Strategic Business Direction - The company is dedicated to developing medical aesthetics and biopharmaceuticals, emphasizing a long-term strategy and resource optimization to enhance operational efficiency and profitability [3][5] - Future business expansion will include exploring new industries and opportunities, with a focus on maintaining a balanced approach to growth and avoiding reckless expansion [5][6] Group 4: Market Conditions and Company Response - The company's stock price has been under pressure due to macroeconomic factors, industry developments, and investor expectations. The company aims to improve product quality, brand building, and customer service to enhance overall competitiveness [6][7] - New medical aesthetics facilities are under construction, with plans for trial operations expected around mid-year [6][7]

Meeting Details - The meeting was held on May 26, 2025, at 14:30, at Suning Global International Center, Nanjing [1] - A total of 288 shareholders and their proxies attended the meeting, representing 62,940,554 shares, which is 2.0741% of the total shares [1][2] Voting Results - The meeting approved the proposals with a total of 1,578,322,418 shares in favor, accounting for 99.8570% of the votes [2] - Among minority shareholders, 60,680,443 shares voted in favor, representing 96.4091% of their voting rights [2] - The voting results showed a consistent trend of high approval rates across multiple proposals, with votes in favor ranging from 99.8553% to 99.8756% [3][4][5][6] Legal Compliance - The meeting complied with all relevant laws, regulations, and the company's articles of association, ensuring the legitimacy of the voting process and results [9]